Echocardiographic analysis of acute effects of percutaneous mitral annuloplasty on severity of secondary mitral regurgitation

Stephan Stöbe*†, Kristin Kreyer‡, Daniel Jurisch, Dietrich Pfeiffer, Daniel Lavall, Gerardo Farese, Ulrich Laufs and Andreas Hagendorff

Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, Leipzig, 04103, Germany

Abstract

Aims Percutaneous mitral annuloplasty (PMA) represents a new treatment option for secondary mitral regurgitation (SMR) being associated with higher morbidity and mortality. The present study was aimed to evaluate whether or not acute effects on SMR severity can quantitatively be assessed after PMA.

Methods and results PMA was performed in 30 patients (mean age 76 ± 9; 37% males) with moderate (n = 14) or severe (n = 16) SMR. Vena contracta (VC), left ventricular (LV) velocity-time-integral ratio (VTIMV/LVOT), effective regurgitant orifice area (EROA) by two-dimensional proximal isovelocity surface area (PISA), regurgitant volume (RVolPISA) and regurgitant fraction (RFPISA) by PISA, RVolvolume and RFvolume by LV volume analyses, and parameters describing LV morphology, function, and cardiac performance were assessed by transthoracic echocardiography prior to and after PMA. According to RFPISA/RFvolume, 14 patients showed mild, 15 moderate, and 1 severe SMR after PMA. Mean RF, RVol, EROA, VC, and VTIMV/LVOT were lower directly after PMA (RFPISA: 49% ± 11 vs. 34% ± 13, P < 0.001; RFvolume: 46% ± 10 vs. 34% ± 13, P < 0.001; RVolPISA: 33 mL ± 13 vs. 25 mL ± 12, P < 0.001; RVolvolume: 28 mL ± 17 vs. 20 mL ± 14, P < 0.05; EROAPISA: 0.24 cm² ± 0.1 vs. 0.19 cm² ± 0.1, P < 0.05; VC: 5.2 ± 0.1 vs. 4.1 ± 0.2, P < 0.001; VTIMV/LVOT: 1.9 ± 0.4 vs. 1.6 ± 0.5, P < 0.05). Parameters of LV morphology, function, and cardiac performance did not change directly after PMA.

Conclusions PMA leads to a reduction of MR severity in >80% of SMR patients. Acute effects of PMA can quantitatively be assessed by transthoracic echocardiography.

Keywords Secondary mitral regurgitation; Percutaneous mitral annuloplasty; Transthoracic echocardiography

Introduction

Mitr al regurgitation (MR) is the second most common valvular heart disease in European countries.1 Whereas components of the mitral apparatus are primarily affected in primary MR, secondary mitral regurgitation (SMR) is caused by alterations, for example, ring dilatation, of the left ventricle or left atrium, while mitral leaflets and chordae are structurally normal.2,3 SMR is associated with an impaired prognosis showing increased mortality in patients after acute myocardial infarction and in heart failure patients.4,5

Treatment of patients with SMR is primarily based on optimal medical treatment of heart failure. Cardiac resynchronization therapy should be evaluated according to the current guidelines in selected patients.3,6 If patients are still symptomatic after optimal conventional treatment, surgical mitral valve repair or interventional mitral valve therapy should be considered.3,6 Surgical mitral annuloplasty should be considered in patients with an acceptable surgical risk, who have no indication or option for myocardial revascularization and/or concomitant valvular heart diseases.3 However, surgical valve repair has never been demonstrated to alter the course of the primary disease or to improve long-term outcome.
mortality in SMR patients.\textsuperscript{3,7} Interventional mitral valve therapy is indicated in high surgical risk patients with severe primary MR and is increasingly established in high surgical risk patients with severe SMR.\textsuperscript{8,9} Interventional mitral valve therapy is mostly performed by the MitraClip procedure, followed by percutaneous mitral annuloplasty (PMA) using the Carillon\textsuperscript{®} Mitral Contour System. Recent trials underline the current perception that treating SMR is important. However, contradictory findings to clinical outcomes are still debatable.\textsuperscript{10,11}

The principle of PMA with the Carillon Mitral Contour Device is based on the stabilization and diminution of the posterior mitral annulus to improve the coaptation of the mitral leaflets. The circumference of the mitral annulus is aimed to be reduced by cinching the proximal and distal anchor after insertion of the device within the coronary sinus.

Previous studies about the Carillon Mitral Contour Device have shown that clinical symptoms and severity of MR have improved over time.\textsuperscript{12–15} In contrast to previous trials, the aim of the present study was to analyse the acute effects of percutaneous mitral annuloplasty with the Carillon Mitral Contour Device on SMR severity, which were quantitatively assessed by transthoracic echocardiography (TTE).

Echocardiography

Transthoracic echocardiography was performed using a GE Vivid 7, Vivid E9, or Vivid E95 system with a MSS phased array probe (GE Healthcare Vingmed Ultrasound AS, Horten, Norway). Echocardiographic analyses were performed using the EchoPac software (version 12.0.1, GE Healthcare Vingmed Ultrasound AS). All investigations and measurements were performed according to national and international recommendations.\textsuperscript{3,16–19}

Assessment of left ventricular and left atrial morphology and function

Left ventricular (LV) end-diastolic (LVEDD) and end-systolic diameters (LVEDS) were assessed by two-dimensional or M-mode measurements in parasternal long or short axis views, respectively. LV end-diastolic (LVEDV), LV end-systolic (LVEDS), and LV total stroke volumes (SV\textsubscript{tot}) and LV ejection fraction were determined by LV biplane planimetry using the modified Simpson’s rule in the apical two-chamber and four-chamber views.\textsuperscript{17} Systolic and diastolic sphericity indices (normal values <0.7) were defined as quotients of the LVEDV or LVEDS in relation to a sphere, which diameter corresponds to the longitudinal axis of the left ventricle.\textsuperscript{18} LV effective stroke volume (SV\textsubscript{eff}) was assessed by LV outflow tract diameter (D\textsubscript{LVOT}) proximal to the aortic valve annulus in the parasternal long axis view and the velocity time integral (VTI) of the LVOT pulsed-wave Doppler signal (VTI\textsubscript{LVOT}) in the apical long axis view according to the equation: SV\textsubscript{eff} = 0.785 × D\textsubscript{LVOT} × VTI\textsubscript{LVOT}. E/E’ was assessed according to the current recommendations and was used to estimate LV end-diastolic filling pressures.\textsuperscript{18} Indexed left atrial (LA) end-diastolic and end-systolic volumes were assessed by LA planimetry in the apical two- and four-chamber views, and LA volume index > 34 mL/m\textsuperscript{2} was defined as abnormal based on the current recommendations.\textsuperscript{18}

Assessment of mitral valve morphology

Mitr valve annulus diameter (D\textsubscript{MVR}) was averaged by measurements in the apical long axis and four-chamber views during maximum expansion in early diastole. Coaptation depth was assessed as the smallest distance between the mitral annular plane and the coaptating leaflets in the centre of the mitral valve. Tenting area was determined by planimetry between the mitral annular plane and the mitral leaflets in the apical long axis view.\textsuperscript{20}
Assessment of semi-quantitative and quantitative parameters for evaluation of secondary mitral regurgitation

Vena contracta (VC) was averaged by the smallest regurgitant jet width in apical long axis and four-chamber views. VTI<sub>LVOT</sub> was assessed by VTI measurements of the pulsed-wave Doppler signal of the transmural inflow and LV outflow. The regurgitant volume (RVol<sub>PISA</sub>) and effective regurgitant orifice area (EROA) were determined by two-dimensional proximal isovelocity surface area (PISA). The regurgitant fraction (RF<sub>PISA</sub>) was calculated by RVol<sub>PISA</sub> divided by SV<sub>tot</sub>. Further, RVol<sub>volume</sub> was calculated by subtracting SV<sub>eff</sub> (stroke volume via LVOT) from SV<sub>tot</sub> (LV planimetry), and RF<sub>volume</sub> was calculated by RVol<sub>volume</sub> divided by SV<sub>tot</sub>. 3,19

Parameters of cardiac performance

SV<sub>eff</sub>, cardiac output (CO) (CO = SV<sub>eff</sub> × heart rate), and cardiac index (CI = CO/body surface area) were determined to characterize cardiac performance. Global longitudinal peak systolic strain (GLPSS) was assessed by speckle tracking analysis of the apical long axis, two- and four-chamber views using a 17-segment model of the left ventricle. 17 Peak power index (PPI) was assessed according to the equation: PPI = (systolic blood pressure × LVOT area × maximum LVOT velocity (V<sub>max</sub>))/LVEDV. 21 Preload recruitable stroke work (PRSW) was determined according to the equation: PRSW = stroke work/LVEDV – K × LVEDV + (1 – K) × LV mass. K is a factor that results from LV mass × 0.0004 + 0.6408, while LV mass was calculated by measuring LVEDD, end-diastolic interventricular septal wall thickness, and LV end-diastolic posterior wall thickness according to the current recommendations. 17,22 Stroke work (SW) describes the SV in relation to blood pressure (RR) conditions and was determined by the equation: SW = SV<sub>eff</sub> × mean RR对此文没有提供具体引用。

End-systolic wall stress (WS) was determined by the equation: WS = (0.334 × RR<sub>systolic</sub> × LVESD)/[(end-systolic LV posterior wall thickness/LVESD)]. 24

Statistical analysis

Data were expressed as mean ± standard deviation. Normality of distribution was tested by Kolmogorov–Smirnov test. Student’s t-test and Wilcoxon matched-pairs test were used for comparison of baseline and follow-up parameters. Statistical significance was considered as P < 0.05 (confidence interval: 95%). Statistical analyses were performed using SPSS software, version 25 (IBM Deutschland GmbH, Ehningen, Germany).

Results

Patient demographics

Patient characteristics are summarized in Table 1. In 19 (63%) patients, SMR was caused by ischaemic cardiomyopathy, and 11 (37%) patients suffered from either dilatative cardiomyopathy or cardiomyopathy due to permanent atrial fibrillation (AF). According to an integrated evaluation using semi-quantitative (VC and VTI<sub>LVOT</sub>) and quantitative echocardiographic parameters (RF<sub>PISA</sub> and RF<sub>volume</sub>), 14 (47%) patients had moderate SMR and 16 (53%) patients had severe SMR prior to PMA. PMA was successfully performed in all patients. During the intervention, the cinching of the posterior mitral annulus was documented by guiding with TEE.

Echocardiographic analyses

According to RF<sub>PISA</sub> and RF<sub>volume</sub>, 14 (47%) patients showed mild, 15 (50%) moderate, and 1 (3%) severe SMR after interventional therapy. In 25/30 patients (83%), an improvement of SMR severity was achieved after PMA in comparison with baseline measurements (Figure 1). Mean RF, RVol, EROA, VC, and VTI<sub>LVOT</sub> were reduced after treatment of SMR (RF-PISA: 49% ± 11 to 34% ± 13, P < 0.001; RF<sub>volume</sub>: 46% ± 10 to 34% ± 13, P < 0.001; RVol<sub>PISA</sub>: 33 mL ± 13 to 25 mL ± 12, P < 0.001; RVol<sub>volume</sub>: 28 mL ± 17 to 20 mL ± 14, P < 0.05; EROA<sub>PISA</sub>: 0.24 cm<sup>2</sup> ± 0.1 to 0.19 cm<sup>2</sup> ± 0.1, P < 0.05; VC: 5.2 ± 0.1 to 4.1 ± 0.2, P < 0.001; VTI<sub>LVOT</sub>: 1.9 ± 0.4 to 1.6 ± 0.5, P < 0.05; Table 2 and Figure 2). Figure 1 highlights

Table 1 Baseline characteristics

| Baseline characteristics | Moderate or severe SMR (n = 30) |
|--------------------------|--------------------------------|
| Male (%)                 | 11 (37)                        |
| Female (%)               | 19 (63)                        |
| Age (years)              | 76 ± 9                         |
| Blood pressure (mmHg)    | 124 ± 19/65 ± 11               |
| NYHA II (%)              | 5 (17)                         |
| NYHA III (%)             | 15 (50)                        |
| NYHA IV (%)              | 10 (33)                        |
| Coronary artery disease (%) | 19 (63)                      |
| Diabetes mellitus (%)    | 10 (33)                        |
| Arterial hypertension (%) | 25 (83)                       |
| Hyperlipidaemia (%)      | 20 (67)                        |
| Obesity (%)              | 3 (10)                         |
| Atrial fibrillation (%)  | 14 (47)                        |
| Pacemaker (%)            | 6 (20)                         |

SMR, secondary mitral regurgitation; NYHA, New York Heart Association.
the practical approach of assessing RVol und RF by different echocardiographic approaches. Significant decreases were observed for DMV, tenting area, and coaptation depth (Table 2). Parameters characterizing LV and LA morphology, LV remodelling, or cardiac performance did not change directly after PMA (Tables 3 and 4).

Subanalysis: non-improvers and improvers

In 5/30 patients (17%), no significant improvement of SMR severity was achieved after PMA. Four patients still showed moderate SMR and one patient severe SMR according to RF<br>volume and RF_PISA (RF<br> PISA: 46% ± 9 to 44% ± 10, P > 0.05; RF<br>volume: 43% ± 8 to 41% ± 10, P > 0.05; RVol_PISA: 31 mL ± 9 to 29 mL ± 8, P > 0.05; RVol<br>volume: 26 mL ± 8 to 27 mL ± 9, P > 0.05; EROA_PISA: 0.22 cm² ± 0.1 to 0.21 cm² ± 0.1, P > 0.05; VC: 4.9 ± 0.2 to 4.6 ± 0.2, P > 0.05; VTI_MV/LVOT: 1.8 ± 0.4 to 1.8 ± 0.3, P > 0.05). All of these patients had (paroxysmal) AF, whereas no significant differences were obtained with respect to other patients’ characteristics.

---

**Figure 1** Example of a patient with (A and B) moderate secondary mitral regurgitation (SMR) prior to and (C and D) mild SMR after percutaneous mitral annuloplasty. Pre- and Postinterventional evaluations both approaches for the assessment of regurgitant volume (RVol) and regurgitant fraction (RF) [(A and C) proximal isovelocity surface area (PISA); (B and D) volume measurements by biplane left ventricular planimetry by Simpson’s rule and Doppler echocardiography] as well as VTIMV/LVOT, and vena contracta are considered. LVOT, left ventricular outflow tract; MV, mitral valve; SV<sub>tot</sub>, total stroke volume; VTI, velocity time integral.

**Table 2** Echocardiographic assessment of parameters describing mitral valve morphology and semi-quantitative and quantitative evaluation of secondary mitral regurgitation

| Parameters                          | Mean ± SD prior to annuloplasty (n = 30) | Mean ± SD after annuloplasty (n = 30) | P (< 0.05) |
|-------------------------------------|-----------------------------------------|---------------------------------------|------------|
| DMV (cm)                            | 3.6 ± 0.6                               | 3.4 ± 0.6                             | <0.001     |
| Tenting area (cm²)                  | 2.2 ± 0.7                               | 1.9 ± 0.6                             | <0.001     |
| Coaptation depth (cm)               | 1.4 ± 0.4                               | 1.3 ± 0.3                             | <0.05      |
| VTIMV/LVOT                          | 1.9 ± 0.4                               | 1.6 ± 0.5                             | <0.05      |
| Vena contracta (mm)                 | 5.2 ± 0.4                               | 4.1 ± 0.2                             | <0.001     |
| EROA_PISA (cm²)                     | 0.24 ± 0.1                              | 0.19 ± 0.1                            | <0.05      |
| RVol<br>volume (mL)                 | 28 ± 17                                 | 20 ± 14                               | <0.05      |
| RF<br>volume (%)                    | 46 ± 10                                 | 34 ± 13                               | <0.001     |
| RVol_PISA (mL)                      | 33 ± 13                                 | 25 ± 12                               | <0.001     |
| RF_PISA (%)                         | 49 ± 11                                 | 34 ± 13                               | <0.001     |

D, diameter; EROA, effective regurgitant orifice area; LVOT, left ventricular outflow tract; MV, mitral valve; PISA, proximal isovelocity surface area; RF, regurgitant fraction; RVol, regurgitant volume; SD, standard deviation; VTI, velocity time integral.
Figure 2  Comparison of semi-quantitative and quantitative parameters for evaluation of secondary mitral regurgitation prior to and after percutaneous mitral annuloplasty. (A) RF$_{PISA}$, (B) RVol$_{PISA}$, (C) vena contracta, and (D) VTI$_{MV/LVOT}$ were significantly lower after percutaneous mitral annuloplasty ($P < 0.05$). RF, regurgitant fraction; RVol, regurgitant volume; VTI, velocity time integral.

Table 3  Echocardiographic assessment of parameters describing left ventricular and left atrial morphology and function

| Parameters                              | Mean ± SD prior to annuloplasty (n = 30) | Mean ± SD after annuloplasty (n = 30) | $P (< 0.05)$ |
|-----------------------------------------|-----------------------------------------|---------------------------------------|--------------|
| LVEDD (cm)                              | 5.9 ± 1.0                               | 5.9 ± 1.0                             | 0.79         |
| LVESD (cm)                              | 4.6 ± 1.1                               | 4.5 ± 1.2                             | 0.31         |
| Sphericity index$_{diast}$              | 0.5 ± 0.2                               | 0.5 ± 0.1                             | 0.27         |
| Sphericity index$_{syst}$               | 0.4 ± 0.2                               | 0.4 ± 0.2                             | 0.32         |
| Indexed LVEDV (mL/m$^2$)                | 93 ± 38                                 | 95 ± 37                               | 0.70         |
| Indexed LVESV (mL/m$^2$)                | 57 ± 31                                 | 55 ± 33                               | 0.60         |
| LVEF (%)                                | 42 ± 13                                 | 45 ± 15                               | 0.06         |
| SV$_{tot}$ (biplane) (mL)               | 67 ± 24                                 | 72 ± 25                               | 0.17         |
| SV$_{eff}$ (mL)                         | 35 ± 14                                 | 45 ± 16                               | $<0.001$     |
| Indexed LAEDV (mL)                      | 47 ± 22                                 | 46 ± 21                               | 0.58         |
| Indexed LAESV (mL)                      | 56 ± 20                                 | 55 ± 20                               | 0.65         |
| E/E'                                     | 18 ± 5                                  | 19 ± 7                                | 0.72         |

LAEDV, left atrial end-diastolic volume; LAESV, left atrial end-systolic volume; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; SD, standard deviation; SV$_{eff}$, effective stroke volume; SV$_{tot}$, total stroke volume.

Table 4  Echocardiographic assessment of parameters describing cardiac performance

| Parameters                              | Mean ± SD prior to annuloplasty (n = 30) | Mean ± SD after annuloplasty (n = 30) | $P (< 0.05)$ |
|-----------------------------------------|-----------------------------------------|---------------------------------------|--------------|
| Global longitudinal strain (%)          | $-12.2 ± 5.59$                          | $-12.3 ± 5.34$                        | 0.39         |
| Cardiac output (L/min)                  | 5.1 ± 1.88                              | 5.4 ± 1.80                            | 0.13         |
| Cardiac index (L/min/m$^2$)             | 2.7 ± 0.88                              | 2.9 ± 0.84                            | 0.13         |
| Total vascular resistance (WU)          | 2.2 ± 0.84                              | 2.0 ± 0.68                            | 0.06         |
| Stroke work (mmHg × mL)                 | 6234 ± 2435                             | 6362 ± 2492                           | 0.35         |
| End-systolic wall stress (mmHg/cm)      | 256 ± 444                               | 201 ± 369                             | 0.09         |
| Preload recruitable stroke work (mmHg)  | 64 ± 21                                 | 66 ± 20                               | 0.35         |
| Peak power index (mmHg/s)               | 406 ± 162                               | 387 ± 157                             | 0.25         |

SD, standard deviation.
After exclusion of non-improvers, improvement of SMR severity was observed by the following: RF_{PISA}: 50% ± 10 to 31% ± 11, P < 0.001; RF_{volume}: 48% ± 9 to 31% ± 11, P < 0.001; RVol_{PISA}: 34 mL ± 10 to 22 mL ± 10, P < 0.001; RVol_{volume}: 31 mL ± 11 to 18 mL ± 10, P < 0.01; EROA_{PISA}: 0.25 cm² ± 0.1 to 0.17 cm² ± 0.1, P < 0.05; VC: 5.4 ± 0.2 to 3.8 ± 0.2, P < 0.001; VTIMV/LVOT: 2.0 ± 0.4 to 1.4 ± 0.3, P < 0.01.

Safety

After PMA, small pericardial effusions were detected in four patients being haemodynamically not relevant in any patient. During the interventional procedure, compressions of branches of the coronary arteries were observed (n = 3, 10%), whereby the circumflex coronary artery was affected in two cases and the right posterolateral branch in one case. However, after readjustment of the device, no myocardial impairment could be documented by speckle tracking analyses in the intraprocedural TEE. In one patient with AF, pacemaker implantation was necessary due to bradyarrhythmia absoluta after PMA.

Discussion

In the present study:

1. Percutaneous mitral annuloplasty leads to a reduction of MR severity in >80% of SMR patients directly after interventional therapy (±3.5 days in average).
2. Reduction of SMR severity can be assessed by morphological (tenting area, D_{MV}, etc.), semi-quantitative (VC, VTIMV/LVOT, RVol, etc.), and quantitative (RF) echocardiographic parameters directly after interventional therapy.
3. Significant differences between both echocardiographic approaches of RVol and RF assessment (PISA and volume measurements) could not be observed.
4. Percutaneous mitral annuloplasty with implantation of the Carillon Mitral Contour System seems to be a safe and effective procedure.

In contrast to previous trials, this is the first study investigating acute effects of percutaneous mitral annuloplasty. AMADEUS, TITAN, TITAN II, and REDUCE-FMR have analysed long-term effects of PMA showing similar results referring to values of D_{MV}, VC, EROA, and RVol after 1–12 months. However, information about RF and the haemodynamic relevance of SMR is not given in previous studies.\(^{12-15}\) In comparison with REDUCE-FMR in the present study, only patients with at least moderate SMR were included.\(^{15}\)

According to the current recommendations, an integrated approach for the assessment of MR is recommended, although PISA and VC are described as favoured approaches under certain circumstances, especially in patients with SMR \(^{3,16,19}\). However, PISA is subjected to multiple limitations leading to overestimation or underestimation of MR severity, particularly eccentric jet formations, crescent-shaped regurgitant orifices, or errors due to the PISA formula itself because of dynamic changes of the regurgitant orifice area during the heart cycle.\(^{3,16,19}\) The assessment of RVol and EROA by PISA does actually not permit estimations of the haemodynamic relevance of SMR, which can only be evaluated by RVol_{PISA} in relation to SV_{tot}. In the present study, severe SMR was characterized by RF considering LV volumes, SV_{tot}, and SV_{eff} and documenting moderate-to-severe and severe SMR prior to interventional therapy (mean RVol_{PISA} of 33 mL ± 13 and mean EROA of 0.24 cm² ± 0.1). Both RVol_{PISA} and EROA are in borderline ranges of moderate SMR according to the current recommendations.\(^{3,16}\) Despite lower values of RVol_{PISA} and EROA in comparison with MITRA-FR (mean EROA: 0.3 cm²) and COAPT trials (mean EROA: 0.4 cm²),\(^{10,11}\) SMR severity can be assumed within comparable ranges with respect to quantification of haemodynamics. In SMR patients being recompensated by optimal medical treatment, it can be expected that CO and CI are within normal ranges prior to and after interventional therapy. The implausibility of echocardiographic parameters (SV_{tot}, SV_{eff}, RVol, and CI values) in recent trials\(^{10,11}\) makes it extremely difficult to interpret these trials.\(^{25,26}\)

The assessment of SV_{tot} and SV_{eff} by biplane LV planimetry and Doppler echocardiography enables another approach for calculation of RVol_{volume} and RF_{volume}, especially in case of inconclusive findings by PISA, VC, and etc.\(^{3,16,19}\) According to the findings of the present study, RVol and RF should be counterchecked by both approaches (LV planimetry/Doppler echocardiography and PISA) with respect to plausibility. However, minor overestimations of RVol_{PISA} in comparison with RVol_{volume} might presumably be due to different SMR jet formations.

Although VC and VTIMV/LVOT were significantly lower after PMA, post-interventional mean VTIMV/LVOT was still >1.4, describing severe MR.\(^{27}\) The incongruence of assessing SMR severity by semi-quantitative parameters including parameters determined by PISA might be explained by methodological issues, different ultrasound settings, and anatomical variations of mitral ring geometry and LA size. Thus, the present study shows that careful assessment of SMR severity, preferably using RF, seems to be essential and should be considered in heart failure patients with reduced LV ejection fraction.

Prior to interventional therapy, LVEDD, LVESD, and indexed LVEDV and LVESV were higher probably due to LV remodelling. Decreased LV volumes in comparison with Lipiecki et al. and Schofer et al. could be explained by different
Further, increased indexed LA end-diastolic and LA end-systolic volumes were observed to be caused by volume overload due to SMR or probably LA remodelling due to atrial fibrillation and hypertensive and/or ischaemic heart disease, respectively. After PMA, no significant differences of these parameters were observed. This is probably due to the nature of LV and LA reverse remodelling, which is a complex and long-term process being influenced by several haemodynamic and neurohumoral factors. Follow-up investigations of the present cohort are needed to clarify whether or not LV and LA remodelling might be induced after reduction of SMR severity after PMA. However, Siminiak et al. have shown that LV reverse remodelling might be induced after PMA after several months. Subanalyses of non-improvers and improvers might point out that positive acute treatment effects could be observed in severe compared with moderate SMR. It can be assumed that acute non-improvers may be appropriate candidates for other mitral valve therapies, for example, concomitant MitraClip procedure. This sets the stage for follow-up studies that will determine the acute effects of combined or mitral valve procedures.

PMA with implantation of the Carillon Mitral Contour System seems to be a safe and effective procedure. Mild adverse events were observed in <20% of the patients. Device associated compressions of marginal branches are known as possible adverse events induced by percutaneous mitral annuloplasty. Territories of marginal branches might have the highest risk of being affected by the procedure due to its anatomical localization adjacent to the coronary sinus. After percutaneous mitral annuloplasty, TTE should be performed to detect further adverse events, for example, pericardial effusion.

Limitations

The power of the study is limited by the small number of patients, which is mainly due to the selected cohort of high-risk patients. Further, the study focuses on the analysis of acute effects of mitral annuloplasty on SMR severity. In the present study, several echocardiographic approaches are used to assess SMR severity. Data sets of another imaging modality, for example, cardiac magnetic resonance imaging, were usually not available because of several contraindications in these highly selected and often critically ill high-risk patients.

Conclusions

Percutaneous mitral annuloplasty (Carillon) leads to a reduction of SMR severity directly after interventional therapy. The present study proves that these acute effects of percutaneous mitral annuloplasty on SMR severity can conclusively be quantified by different echocardiographic approaches.

Conflict of interest

None declared.

References

1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A. A prospective survey of patients with valvular heart disease in Europe. The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24: 1231–1243.
2. Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. The Lancet 2009; 373: 1382–1394.
3. Baumgartner H, Falk V, Bash J, De Bonis M, Hamm C, Holm PJ, Jung B, Lancellotti P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjögren J, Mas PT, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017; 38: 2739–2791.
4. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey RR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001; 103: 1759–1764.
5. Goliaei G, Bartko PE, Pavo N, Neuhold S, Wurm R, Mascherbauer J, Lang IM, Strunk G, Hülsmann M. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J 2018; 39: 39–46.
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Piecha B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 18: 891–975.
7. Milano CA, Daneshmand MA, Rankin JS, Honeycutt E, Williams ML, Swaminathan M, Linblad L, Shaw LK, Glower DD, Smith PK. Survival prognosis and surgical management of ischemic mitral regurgitation. Ann Thorac Surg 2008; 86: 735–744.
8. Feldman T, Fernandes E, Levisay JP. Transcatheter mitral valve repair/replacement for primary mitral regurgitation. Ann Cardiothorac Surg 2018; 7: 755–763.
9. Lim DS, Reynolds MR, Feldman T, Kar S, Herrmann HC, Wang A, Whitlow PL, Gray WA, Grayburn P, Mack MJ, Glower DD. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral
regurgitation following transcatheter mitral valve repair with the MitraClip® system. *J Am Coll Cardiol* 2014; 64: 182–192.

10. Obadia JF, Messika-Zeitoun D, Leurent G, Jung B, Bonnet G, Piriot N, Lefèvre T, Pirot C, Rouleau F, Carrié D, Nejjar M, Ohlmann P, Leclercq F, Saint Etienne C, Teiger E, Leroux L, Karam N, Michel N, Gilard M, Donal E, Trochu JN, Cormier B, Armony X, Boutitie F, Maucourt-Boukl D, Barcel N, Samson G, Guerin P, Vahanian A, Mewton N, MITRA-FR Investigators. Percutaneous repair or medical treatment for secondary mitral regurgitation. *N Engl J Med* 2018; 379: 2297–2306.

11. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock LJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018; 379: 2307–2318.

12. Schofer J, Siminiak T, Haude M, Herrmann JP, Vainer J, Wu JC, Levy WC, Mauri L, Feldman T, Kwong RY, Kaye DM, Duffy SJ, Tübler T, Degen H, Brandt MC, van Bibber R, Goldberg S, Reuter DG, Hoppe UC. Percutaneous mitral annuloplasty for functional mitral regurgitation. Results of the CARILLON Mitral Annuloplasty Device European Union Study. *Circulation* 2009; 120: 326–333.

13. Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, Fajadet J, Shah AM, Feldman T, Kaye DM, Goldberg SL, Levy WC, Solomon SD, Reuter DG. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN trial. *Eur J Heart Fail* 2012; 14: 931–938.

14. Lipiecki J, Siminiak T, Sievert H, Müller-Ehmsen J, Degen H, Wu J, Schandrin C, Kalmuecki P, Hofmann J, Reuter D, Goldberg SL, Haude M. Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation. The TITAN II trial. *Open Heart* 2016; 3: e000411.

15. Witte KK, Lipiecki J, Siminiak T, Meredith IT, Malkin CJ, Goldberg SL, Stark MA, von Bardeleben RS, Cremer PC, Jaber WA, Celemajer DS, Kaye DM, Sievert H. The REDUCE FMR trial: a randomized sham-controlled study of percutaneous mitral annuloplasty in functional mitral regurgitation. *JACC Heart Fail* 2019; 7: 945–955.

16. Zoghbi WA, Adama D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, Hahn RT, Han Y, Hung J, Lang RM, Little SH, Shah DJ, Sherman S, Thavendiranathan P, Thomas JD, Weissman NJ. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr* 2017; 30: 303–371.

17. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Marino P, Oh JK, Popescu BA, Wagoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2015; 16: 233–270.

18. Naghue SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Ob JK, Popescu BA, Wagoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016; 29: 277–314.

19. Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pibarot A, Badano LP, Bax JJ, Bermejo A, Chauveau P, Delain S, Fournier L, Graham T, Herold T, Kaye DM, Kharbanda OP, Labata A, Labotka R, Testa D, Vahanian A, Vilahur G, Wijns W, Vos C, Zamorano JL. Task force on the management of valvular heart disease of the European Society of Cardiology developed in collaboration with the Society of Interventional Cardiology of the European Association for Cardiovascular Imaging. *Eur Heart J* 2017; 38: 2974–3034.

20. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol* 2000; 35: 569–582.

21. Zamorano JL, Badano LP, Bruce C, Chan KL, Gonçalves A, Hahn RT, Keane MG, La Canna G, Monaghan MJ, Nihoyannopoulos P, Silvestry FE, Vanoverschelde JL, Gillam LD. EAE/AESE recommendations for the use of echocardiography in new transcatheter interventions for valvular heart disease. *Eur Heart J* 2011; 32: 2189–2214.